In this model, neither anti-PD-1 nor anti-PD-L1 monotherapy has shown significant efficacy; however, AFP immunotherapy combined with anti-PD-L1 can significantly inhibit the progression of HCC, while the combination with anti-PD-1 can induce a slowdown in tumor progression [170]. Here, AFP is linked to hepatocellular carcinoma.